LBA86 Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial

医学 恩扎鲁胺 前列腺癌 卡巴齐塔塞尔 生物标志物 肿瘤科 多西紫杉醇 危险系数 内科学 雄激素受体 临床终点 随机对照试验 紫杉烷 癌症 雄激素剥夺疗法 置信区间 乳腺癌 化学 生物化学
作者
Henrik Grönberg,Johan Lindberg,Bram De Laere,Alessio Crippa,Andrea Discacciati,Camilla Thellenberg Karlsson,Anders Ullén,Elin Jänes,Ashkan Mortezavi,Piet Ost,Gunilla Enblad,Jan Oldenburg,J. Sandzén,Linn Pettersson,M.N. Vigmostad,Marie Hjälm-Eriksson,Mats J. Olsson,Peter Schatteman,Christophe Ghysel,Martin Eklund
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S1327-S1327
标识
DOI:10.1016/j.annonc.2023.10.088
摘要

The Prostate Biomarker (ProBio) trial is an international biomarker-driven, randomized, outcome-adaptive platform trial in men with metastatic castrate resistant prostate cancer (mCRPC) evaluating multiple agents. We used outcome-adaptive randomization to compare biomarker-driven treatment selection (experimental arms) against physician’s choice standard-of-care (SOC; control arm), and to compare agents against each other within the experimental treatment arms. Men with mCRPC were randomized based on genomic alterations in circulating tumor DNA in five biomarker signatures: (1) AR wt and TP53 wt; (2) TP53 mut; (3) DRD; (4) TMPRSS2:ERG fusion; (5) all biomarkers signatures combined. Androgen receptor pathway inhibitors (ARPi; abiraterone and enzalutamide) and taxanes (docetaxel and cabazitaxel) were evaluated, using progression-free survival, by no longer clinically benefiting per PCWG3 criteria (PFS), as primary endpoint. Enrollment in the experimental group was stopped when the Bayesian probability of superiority reached prespecified thresholds (“graduation”). In total, 219 men were randomized: 92 to SOC, vs. 76 and 51 to taxanes and ARPi, respectively, in the biomarker-driven arms. ARPi graduated in the “signature all”, i.e. a signature encompassing all biomarkers. The median estimated PFS was 11.3 months (90% Bayesian credible interval [CI], 9.8 to 13.1) for ARPi compared with 7.2 months (90% CI, 6.5 to 8.1) in the SOC arm, for a hazard ratio (HR) of 0.52 (90% CI 0.37 to 0.72). ARPi demonstrated superiority to taxanes within the experimental arms (HR 0.54; 90% CI 0.38 to 0.76). We observed suggestive differential treatment effects for patients with TP53 mut and TMPRSS2:ERG fusion disease. The median estimated overall survival (OS) was 37.3 months (CI, 27.7 to NA) for ARPi compared with 20.2 months (90% CI, 18.4 to 23.0) taxanes within the experimental arms. ARPi increases PFS and OS both compared to SOC and taxanes in patients with mCRPC. These are directly randomized data for ARPi and taxanes, showing the first evidence of a difference in PFS and OS for these agents in the mCRPC setting.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
dong应助Yuelong采纳,获得10
5秒前
bingsu108完成签到,获得积分10
6秒前
小岚花发布了新的文献求助10
8秒前
CodeCraft应助凉茶采纳,获得10
8秒前
脑洞疼应助YZQ采纳,获得10
9秒前
琳琳完成签到,获得积分10
9秒前
华仔应助俏皮的白柏采纳,获得10
10秒前
羊洋洋完成签到,获得积分20
10秒前
最爱地瓜和虾滑完成签到 ,获得积分10
12秒前
yar给聪慧的草丛的求助进行了留言
12秒前
奋斗雁山发布了新的文献求助10
12秒前
13秒前
查到文献了吗完成签到,获得积分10
13秒前
FashionBoy应助Lee采纳,获得10
13秒前
Elvira完成签到,获得积分10
13秒前
15秒前
17秒前
易酰水烊酸应助Onism采纳,获得10
17秒前
青岚完成签到 ,获得积分10
17秒前
18秒前
tay发布了新的文献求助10
19秒前
20秒前
pluto应助一直小虾米采纳,获得10
20秒前
双楠应助不想采纳,获得10
22秒前
23秒前
Luobing完成签到,获得积分10
24秒前
研友_LXjjOZ完成签到,获得积分10
24秒前
上官若男应助蔚蓝的天空采纳,获得10
25秒前
slr完成签到,获得积分10
25秒前
逆境发布了新的文献求助10
25秒前
26秒前
草莓布丁发布了新的文献求助80
27秒前
凉茶发布了新的文献求助10
28秒前
28秒前
30秒前
30秒前
30秒前
30秒前
yyyq发布了新的文献求助10
31秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988838
求助须知:如何正确求助?哪些是违规求助? 3531250
关于积分的说明 11252914
捐赠科研通 3269838
什么是DOI,文献DOI怎么找? 1804820
邀请新用户注册赠送积分活动 881943
科研通“疑难数据库(出版商)”最低求助积分说明 809028